In the wake of negative market reaction to Phase II data for its non-alcoholic steatohepatitis candidate, Intercept Pharmaceuticals Inc. is arguing that benefit seen in reducing fibrosis should more than counterbalance concerns about slightly increased LDL levels seen in the same study.
Intercept has seen its share price tumble since a Nov. 7 Lancet article provided the fullest picture yet of obeticholic...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?